157 related articles for article (PubMed ID: 35890123)
1. Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer Cells.
Maietta I; Martínez-Pérez A; Álvarez R; De Lera ÁR; González-Fernández Á; Simón-Vázquez R
Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890123
[TBL] [Abstract][Full Text] [Related]
2. Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy.
Laschanzky RS; Humphrey LE; Ma J; Smith LM; Enke TJ; Shukla SK; Dasgupta A; Singh PK; Howell GM; Brattain MG; Ly QP; Black AR; Black JD
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31500290
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo.
Chen YH; Chen YC; Lin CC; Hsieh YP; Hsu CS; Hsieh MC
Cancer Manag Res; 2020; 12():4645-4665. PubMed ID: 32606957
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
[TBL] [Abstract][Full Text] [Related]
5. The anti-tumor effect of HDAC inhibition in a human pancreas cancer model is significantly improved by the simultaneous inhibition of cyclooxygenase 2.
Peulen O; Gonzalez A; Peixoto P; Turtoi A; Mottet D; Delvenne P; Castronovo V
PLoS One; 2013; 8(9):e75102. PubMed ID: 24040391
[TBL] [Abstract][Full Text] [Related]
6. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
[TBL] [Abstract][Full Text] [Related]
7. Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer.
Tian YF; Wang HC; Luo CW; Hung WC; Lin YH; Chen TY; Li CF; Lin CY; Pan MR
Am J Cancer Res; 2018; 8(9):1812-1822. PubMed ID: 30323973
[TBL] [Abstract][Full Text] [Related]
8. MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis.
Du L; Wang D; Wei X; Liu C; Xiao Z; Qian W; Song Y; Hou X
BMC Gastroenterol; 2022 Jan; 22(1):29. PubMed ID: 35062876
[TBL] [Abstract][Full Text] [Related]
9. Differential Gemcitabine Sensitivity in Primary Human Pancreatic Cancer Cells and Paired Stellate Cells Is Driven by Heterogenous Drug Uptake and Processing.
Amrutkar M; Vethe NT; Verbeke CS; Aasrum M; Finstadsveen AV; Sántha P; Gladhaug IP
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33287390
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J
J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810
[TBL] [Abstract][Full Text] [Related]
11. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
Roca MS; Moccia T; Iannelli F; Testa C; Vitagliano C; Minopoli M; Camerlingo R; De Riso G; De Cecio R; Bruzzese F; Conte M; Altucci L; Di Gennaro E; Avallone A; Leone A; Budillon A
J Exp Clin Cancer Res; 2022 Mar; 41(1):83. PubMed ID: 35241126
[TBL] [Abstract][Full Text] [Related]
12. N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2.
Yao M; Hong Y; Liu Y; Chen W; Wang W
Exp Ther Med; 2017 Sep; 14(3):2101-2107. PubMed ID: 28962130
[TBL] [Abstract][Full Text] [Related]
13. Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells.
Gao Y; Chen MK; Chu YY; Yang L; Yu D; Liu Y; Hung MC
Am J Cancer Res; 2021; 11(1):236-250. PubMed ID: 33520371
[TBL] [Abstract][Full Text] [Related]
14. Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling.
Yu S; Wang L; Che D; Zhang M; Li M; Naito M; Xin W; Zhou L
J Exp Clin Cancer Res; 2022 Mar; 41(1):88. PubMed ID: 35260193
[TBL] [Abstract][Full Text] [Related]
15. High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma.
Stenzinger A; Endris V; Klauschen F; Sinn B; Lorenz K; Warth A; Goeppert B; Ehemann V; Muckenhuber A; Kamphues C; Bahra M; Neuhaus P; Weichert W
BMC Cancer; 2013 Oct; 13():450. PubMed ID: 24088390
[TBL] [Abstract][Full Text] [Related]
16. KMT2D deficiency enhances the anti-cancer activity of L48H37 in pancreatic ductal adenocarcinoma.
Li SS; Jiang WL; Xiao WQ; Li K; Zhang YF; Guo XY; Dai YQ; Zhao QY; Jiang MJ; Lu ZJ; Wan R
World J Gastrointest Oncol; 2019 Aug; 11(8):599-621. PubMed ID: 31435462
[TBL] [Abstract][Full Text] [Related]
17. Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment.
Elrakaybi A; Ruess DA; Lübbert M; Quante M; Becker H
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497404
[TBL] [Abstract][Full Text] [Related]
18. An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors.
Tinari N; De Tursi M; Grassadonia A; Zilli M; Stuppia L; Iacobelli S; Natoli C
Curr Cancer Drug Targets; 2012 May; 12(4):439-52. PubMed ID: 22309455
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
20. Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.
Lu Z; Tian Y; Salwen HR; Chlenski A; Godley LA; Raj JU; Yang Q
Anticancer Drugs; 2013 Jun; 24(5):484-93. PubMed ID: 23466651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
